Glioblastoma: What Do We Know?

Dear Colleagues,

Glioblastoma multiforme (GBM) is a common primary astrocytoma and represents the most malignant tumor in the central nervous system. The fast progression of this tumor and short survival time of GBM patients have been a tough challenge in cancer research and clinical treatment. Despite advances in recent years, GBM remains largely incurable. Little is known about the etiology of GBM, although high-dose ionizing radiation is recognized as a risk factor. GBM shows heterogeneous features involving multiple cell types, including cancer stem cells, hemorrhage, necrosis, aggressive invasion, and vascular endothelial hyperplasia, among other malignant features. Primary and secondary GBMs are characterized by molecular correlates, aberrations of signaling pathways, genetic mutations, and altered gene expression. Early detection and accurate monitoring of carcinoma are critical for early diagnosis, effective treatment, and improved patient outcomes. Biomarkers, such as miRNAs, can be valuable in these applications. In the last few years, genetic modifications, such as the reprogramming of cancer cells into non-cancerous phenotypes, provide an exciting opportunity of stopping tumor growth by a gene therapy. Recent advances in imaging techniques, such as MRI and PET, have also helped in evaluating the changes in the hemodynamics, tissue architecture, and cellular metabolism of gliomas. All of these studies raise the hope for improved therapeutics and the development of a new paradigm for the management of GBM. This Special Issue aims to enhance our knowledge about GBM by sharing the most recent advances in basic and clinical investigations. We welcome articles and reviews of cellular/molecular mechanisms and possible pathogenesis. We especially encourage innovative approaches and strategies that show the potential mechanisms of novel treatments or significantly improved GBM therapy.

Prof. Dr. Shan Ping Yu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• carcinoma cell
• diagnoses
• molecular mechanism
• cellular mechanism
• signaling pathways
• biomarkers
• therapeutics